Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMH-010 in Advanced Malignant Solid Tumors
NCT04343859Phase 1Unknown
- Sponsor
- Tianjin Chase Sun Pharmaceutical
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMMH-010 in malignant solid tumor, sponsored by Tianjin Chase Sun Pharmaceutical. Primary endpoints: Dose-limiting toxicity and Adverse reaction rate. Status: unknown.
02
Drugs
IMMH-010
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04343859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343859.